Cole, Am J Sports Med 2023 - Prospective Randomized Trial of Biologic Augmentation with Bone Marrow Aspirate Concentrate in Patients Undergoing Arthroscopic Rotator Cuff Repair - Article Summary

Prospective Randomized Trial of Biologic Augmentation with Bone Marrow Aspirate Concentrate in Patients Undergoing Arthroscopic Rotator Cuff Repair

Cole, Verma, et al.·Am J Sports Med·2023·62 citations·RCT

Background

Although initial studies have demonstrated that concentrated bone marrow aspirate (cBMA) injections promote rotator cuff repair (RCR) healing, there are no randomized prospective studies investigating clinical efficacy.

Purpose

To compare outcomes after arthroscopic RCR (aRCR) with and without cBMA augmentation. It was hypothesized that cBMA augmentation would result in statistically significant improvements in clinical outcomes and rotator cuff structural integrity.

Methods

Study Design: Randomized controlled trial; Level of evidence, 1.

Patients indicated for aRCR of isolated 1- to 3-cm supraspinatus tendon tears were randomized to receive adjunctive cBMA injection or sham incision.
Bone marrow was aspirated from the iliac crest, concentrated using a commercially available system, and injected at the aRCR site after repair.
Patients were assessed preoperatively and serially until 2 years postoperatively via the following functional indices: American Shoulder and Elbow Surgeons (ASES), Single Assessment Numeric Evaluation (SANE), Simple Shoulder Test, 12-Item Short Form Health Survey, and Veterans RAND 12-Item Health Survey.
Magnetic resonance imaging (MRI) was performed at 1 year to assess rotator cuff structural integrity according to Sugaya classification.
Treatment failure was defined as decreased 1- or 2-year ASES or SANE scores as compared with preoperative baseline, the need for revision RCR, or conversion to total shoulder arthroplasty.

Results

An overall 91 patients were enrolled (control, n = 45; cBMA, n = 46): 82 (90%) completed 2-year clinical follow-up and 75 (82%) completed 1-year MRI.
Functional indices significantly improved in both groups by 6 months and were sustained at 1 and 2 years (all P < .05).
The control group showed significantly greater evidence of rotator cuff retear according to Sugaya classification on 1-year MRI (57% vs 18%; P < .001).
Treatment failed for 7 patients in each group (control, 16%; cBMA, 15%).

Conclusions

cBMA-augmented aRCR of isolated supraspinatus tendon tears may result in a structurally superior repair but largely fails to significantly improve treatment failure rates and patient-reported clinical outcomes when compared with aRCR alone. Additional study is warranted to investigate the long-term benefits of improved repair quality on clinical outcomes and repair failure rates.

Supplemental

Prospective Randomized Trial of Biologic Augmentation with Bone Marrow Aspirate Concentrate in Patients Undergoing Arthroscopic Rotator Cuff Repair.